EU Addresses Clinical Trial Integrity Concerns In Face Of COVID-19 Crisis
Risk Assessment Of Pandemic Impact Should Be Done On Blinded Data
Executive Summary
EU guidance offers high-level recommendations on the steps that clinical trial sponsors should take to assess the impact of COVID-19 on the quality and reliability of data being generated in ongoing studies. Early scientific advice is recommended if changes must be made to existing protocols or data analysis plans.